Literature DB >> 27225749

Immunohistochemical Expression and Serum Levels of CD44 as Prognostic Indicators in Patients with Non-Small Cell Lung Cancer.

Shinji Shinohara1, Takeshi Hanagiri, Akihiro Taira, Masaru Takenaka, Soichi Oka, Yasuhiro Chikaishi, Hidetaka Uramoto, Tomoko So, Sohsuke Yamada, Fumihiro Tanaka.   

Abstract

BACKGROUND/
OBJECTIVES: CD44 is often expressed in various types of tumor cells and involved in a number of biological behaviors of malignancy. The present study focused on the clinical significance of the expression of CD44st and CD44v6 in non-small cell lung cancer (NSCLC).
METHODS: The cohort consisted of 261 consecutive patients who had undergone complete resection of NSCLC. CD44 expression was evaluated in surgical specimens by immunohistochemical staining. Serum CD44 levels were determined using a sandwich ELISA (enzyme-linked immunosorbent assay).
RESULTS: In the immunohistochemical analysis, significant correlations were observed between CD44 expression and clinicopathological factors such as the T factor, N factor, pathological stage, and histological type. The 5-year survival rates according to CD44v6 expression were 65.8 and 80.6% in the higher and lower expression groups, respectively (p = 0.0053). According to ELISA, the group with higher expression of serum CD44v6 also showed a significantly more unfavorable prognosis than the lower expression group (p = 0.014). According to multivariate analysis using these significant variables, serum CD44v6 level was found to be an independent prognostic factor (p = 0.048).
CONCLUSIONS: CD44v6 overexpression and higher serum CD44v6 levels were found to be significantly unfavorable prognostic factors.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27225749     DOI: 10.1159/000445951

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  10 in total

1.  Inflammation-Related DNA Damage and Cancer Stem Cell Markers in Nasopharyngeal Carcinoma.

Authors:  Shumin Wang; Ning Ma; Weilin Zhao; Kaoru Midorikawa; Shosuke Kawanishi; Yusuke Hiraku; Shinji Oikawa; Zhe Zhang; Guangwu Huang; Mariko Murata
Journal:  Mediators Inflamm       Date:  2016-08-28       Impact factor: 4.711

2.  CD44 Gene Polymorphisms as a Risk Factor for Susceptibility and Their Effect on the Clinicopathological Characteristics of Lung Adenocarcinoma in Male Patients.

Authors:  Ju-Pi Li; Ming-Ju Hsieh; Ying-Erh Chou; Yu-Hua Chao; Thomas Chang-Yao Tsao; Shun-Fa Yang
Journal:  Int J Environ Res Public Health       Date:  2020-04-25       Impact factor: 3.390

3.  Breast cancer stem cell markers CD44 and ALDH1A1 in serum: distribution and prognostic value in patients with primary breast cancer.

Authors:  Yanan Kong; Ning Lyu; Jiali Wu; Hailin Tang; Xinhua Xie; Lu Yang; Xing Li; Weidong Wei; Xiaoming Xie
Journal:  J Cancer       Date:  2018-09-08       Impact factor: 4.207

4.  Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma.

Authors:  Yudong Wu; Xia Yu; Mingzhu Liang; Baojun Wang
Journal:  Oncol Lett       Date:  2019-07-30       Impact factor: 2.967

5.  Serum expression of Vascular Endothelial-Cadherin, CD44, Human High mobility group B1, Kallikrein 6 proteins in different stages of laryngeal intraepithelial lesions and early glottis cancer.

Authors:  Michał Żurek; Anna Rzepakowska; Iwona Kotuła; Urszula Demkow; Kazimierz Niemczyk
Journal:  PeerJ       Date:  2022-04-19       Impact factor: 3.061

6.  RNA-binding protein CELF6 modulates transcription and splicing levels of genes associated with tumorigenesis in lung cancer A549 cells.

Authors:  HuSai Ma; GuoWei Liu; Bin Yu; Joshua Wang; YaLi Qi; YiYing Kou; Ying Hu; ShunJun Wang; Fei Wang; Dong Chen
Journal:  PeerJ       Date:  2022-07-26       Impact factor: 3.061

7.  Aptamer-siRNA chimera and gold nanoparticle modified collagen membrane for the treatment of malignant pleural effusion.

Authors:  Wen Chen; Fengjie Guo; Zhipeng Ren; Linghui Wang; Tinghui Li; Xiaobin Hou
Journal:  Front Bioeng Biotechnol       Date:  2022-08-23

8.  CD44 promotes cell proliferation in non-small cell lung cancer.

Authors:  Bo Hu; Yuanyuan Ma; Yue Yang; Lijian Zhang; Haibo Han; Jinfeng Chen
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

Review 9.  Cancer Stem Cells-Origins and Biomarkers: Perspectives for Targeted Personalized Therapies.

Authors:  Lia Walcher; Ann-Kathrin Kistenmacher; Huizhen Suo; Reni Kitte; Sarah Dluczek; Alexander Strauß; André-René Blaudszun; Tetyana Yevsa; Stephan Fricke; Uta Kossatz-Boehlert
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

10.  [Expression of CD44 in Tumor Tissue and Serum of Small Cell Lung Cancer and Its Clinical Prognostic Significance].

Authors:  Ying Wang; Yi Guo; Haifeng Lin; Lina Zhang; Hongmei Zhang; Qunhui Wang; Fanbin Hu; Jie Li; Baolan Li; Tongmei Zhang
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-06-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.